title: Central nervous system remyelination in culture--a tool for multiple sclerosis research.
abstract: Multiple sclerosis is a demyelinating disease of the central nervous system which only affects humans. This makes it difficult to study at a molecular level, and to develop and test potential therapies that may change the course of the disease. The development of therapies to promote remyelination in multiple sclerosis is a key research aim, to both aid restoration of electrical impulse conduction in nerves and provide neuroprotection, reducing disability in patients. Testing a remyelination therapy in the many and various in vivo models of multiple sclerosis is expensive in terms of time, animals and money. We report the development and characterisation of an ex vivo slice culture system using mouse brain and spinal cord, allowing investigation of myelination, demyelination and remyelination, which can be used as an initial reliable screen to select the most promising remyelination strategies. We have automated the quantification of myelin to provide a high content and moderately-high-throughput screen for testing therapies for remyelination both by endogenous and exogenous means and as an invaluable way of studying the biology of remyelination.
authors.affiliation: MS Centre, Centre for Regenerative Medicine, University of Edinburgh, Queen's Medical Research Centre, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Jarjour
authors.forename: Amanda
authors.initials: A
authors.lastname: Boyd
authors.forename: Anna
authors.initials: A
authors.lastname: Williams
mesh_terms: D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D000941:Antigens / Q000378:metabolism; D001973:Bromodeoxyuridine / Q000378:metabolism; D049109:Cell Proliferation; D002490:Central Nervous System / Q000187:drug effects / Q000502:physiology*; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology*; D049452:Green Fluorescent Proteins / Q000235:genetics; D008244:Lysophosphatidylcholines / Q000633:toxicity; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D004676:Myelin Basic Protein / Q000378:metabolism*; D009186:Myelin Sheath / Q000378:metabolism / Q000502:physiology*; D016900:Neurofilament Proteins / Q000378:metabolism; D009836:Oligodendroglia / Q000502:physiology; D009924:Organ Culture Techniques; D011509:Proteoglycans / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D013234:Stem Cells / Q000502:physiology; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D000941:Antigens; D001973:Bromodeoxyuridine; D049452:Green Fluorescent Proteins; D008244:Lysophosphatidylcholines; D004676:Myelin Basic Protein; D016900:Neurofilament Proteins; D011509:Proteoglycans; D012333:RNA, Messenger; D000099216:Chondroitin Sulfate Proteoglycan 4; C051774:neurofilament protein H